engleski

A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate-statin combination therapy

Patients who have elevated triglyceride levels plus low levels of HDL-c are most likely to achieve clinical benefit from fenofibrate - statin combination therapy. In these patients with AD, achieving target non-HDL-c levels should be a key focus of CV risk management, and the use of non- HDL-c was advocated to provide a better measure of CV risk than LDL-c levels.

atherogenic dyslipidaemia ; cardiovascular risk ; cholesterol ; combination therapy ; fenofibrate ; statins ; tryglicerides

nije evidentirano